Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Nov 20:43:30-33.
doi: 10.1016/j.jdcr.2023.09.042. eCollection 2024 Jan.

A case of urticarial vasculitis associated with atezolizumab

Jade N Young  1 , Ryan Rivera-Oyola  1 , Dina Poplausky  1 , Yamato Suemitsu  2 , Randie H Kim  1 , Deborah Doroshow  3 , Nicholas Gulati  1
Affiliations
Case Reports

A case of urticarial vasculitis associated with atezolizumab

Jade N Young et al. JAAD Case Rep. .
No abstract available

Keywords: atezolizumab; cirAE; cutaneous immune-related adverse event; immune checkpoint inhibitor; immune-related adverse event; irAE; urticarial vasculitis; vasculitis.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Faintly erythematous, edematous tender plaques on the right arm lasting >24 hours consistent with urticarial vasculitis.
Fig 2
Fig 2
Histopathology demonstrating sparse perivascular dermatitis (A, ×50, low power), neutrophilic and eosinophilic infiltrate (B, ×200 interstitial), neutrophils within the blood vessel walls with leukocytoclasia, extravasated erythrocytes, and hints of fibrin deposition within the vessel walls (C, ×200 perivascular).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Tan S., Day D., Nicholls S.J., Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2022;4(5):579–597. doi: 10.1016/j.jaccao.2022.09.004. - DOI - PMC - PubMed
    1. Geisler A.N., Phillips G.S., Barrios D.M., et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268. doi: 10.1016/j.jaad.2020.03.132. - DOI - PMC - PubMed
    1. Daxini A., Cronin K., Sreih A.G. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37(9):2579–2584. doi: 10.1007/s10067-018-4177-0. - DOI - PubMed
    1. Zhong H., Zhou J., Xu D., Zeng X. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. Asia Pac J Clin Oncol. 2021;17(3):178–185. doi: 10.1111/ajco.13346. - DOI - PMC - PubMed
    1. Gu S.L., Jorizzo J.L. Urticarial vasculitis. Int J Womens Dermatol. 2021;7(3):290–297. doi: 10.1016/j.ijwd.2021.01.021. - DOI - PMC - PubMed

Publication types

LinkOut - more resources